Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Empagliflozin for Epilepsy
NCT05512130Phase 1Unknown
- Sponsor
- Washington University School of Medicine
- Start
- Aug 2022
- Primary completion
- Mar 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of empagliflozin in epilepsy (2 arms), sponsored by Washington University School of Medicine. Primary endpoints: Change in blood beta-hydroxybutyrate while on empagliflozin at 2 weeks, Change in blood glucose while on empagliflozin at 2 weeks and 1 more. Status: unknown.
02
Drugs
empagliflozin
03
Conditions
epilepsy
Beyond the preview
Go deeper on NCT05512130.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05512130.